Executive summary
US 6,258,791 is a platform-style US composition and method patent covering co-administration (or formulation) of hyaluronidase with nucleic acid delivery systems, with explicit coverage for adenoviral vectors and typical non-viral carriers (cationic lipids, liposomes, cationic polymers). The core novelty is use of a hyaluronidase “matrix disorganizer” to enhance intracellular delivery of nucleic acids, including infectious viral particles. For business use, the claims read like a broad technology patent that can support licensing or settlement leverage against competitors using hyaluronidase as a delivery enhancer in conjunction with gene transfer payloads. However, enforceable leverage in current years is largely time-limited because the patent’s term and any US exclusivity typically expired, and freedom-to-operate is now dominated by earlier/later hyaluronidase-gene-delivery patents, formulations, and any post-issuance continuations.
H1: US Patent 6,258,791 claims analysis and patent landscape for hyaluronidase-enhanced nucleic acid delivery
What patents protect hyaluronidase-enhanced delivery of nucleic acids in the US?
US 6,258,791 protects hyaluronidase as the enabling agent for nucleic acid delivery enhancement, paired with nucleic acid carried by either (i) infectious viral particles or (ii) cationic lipid/liposome/cationic polymer complexes. The claim language is not limited to a specific therapeutic gene or promoter; it is centered on the delivery-enabling co-factor (hyaluronidase) and carrier type.
What is the protected subject matter by claim group?
Composition claims (1-7)
- Claim 1: composition including (a) at least one nucleic acid and (b) at least one hyaluronidase that disorganizes extracellular matrix, where nucleic acid is contained in an infectious viral particle or carried by non-viral systems (cationic lipid, liposome, or cationic polymer).
- Claim 2: narrows hyaluronidase to specific classes/sources: mammalian, reptilian, hymenopteran hyaluronate glycanohydrolase; salivary gland leech hyaluronate glycanohydrolase; or bacterial hyaluronate lyase.
- Claims 3-6: narrows viral carrier to recombinant adenoviral vector defective for replication, with explicit deletions in adenoviral early/late regions (E1 required to be absent/partially absent; optional E3 deletion; optional deletion of E2/E4/L1-L5 region set).
- Claim 7: adds pharmaceutically acceptable excipient (generic but helpful for practice/enablement).
Method claims (8-12)
- Claim 8: method to enhance delivery of nucleic acid into a human or animal by administering hyaluronidase prior to or in conjunction with an infectious viral particle or with a nucleic acid complex using cationic lipid/liposome/cationic polymer.
- Claim 9 and 10: time-of-administration permutations: simultaneous with the infectious particle/complex or following hyaluronidase.
- Claims 11-12: fix the infectious particle to adenovirus for the simultaneous and sequential versions.
Kit claim (13)
- A kit containing (i) at least hyaluronidase and (ii) at least one nucleic acid with the same carrier limitations as composition claim 1.
Scope implications for competitor products
From a claim construction perspective, US 6,258,791 is designed to capture:
- Gene therapy vectors where the payload is delivered using adenoviral vectors and where hyaluronidase is administered as an enhancer (pre, concurrent, or simultaneous).
- Non-viral gene delivery systems (cationic lipid/liposome/cationic polymer complexes) where hyaluronidase is co-delivered.
- Formulation and kit deployments, not only in vivo dosing schedules.
Its “open” language (“infectious viral particle” and “cationic lipid/liposome/cationic polymer”) increases the number of ways a design-around must be evaluated: changing the carrier class alone may not be sufficient if hyaluronidase is still used as the enhancer.
How strong is the patent estate for hyaluronidase + gene delivery based on these claims?
Strength is driven by breadth of claim elements and the number of axis-of-variation the patentee locked in. US 6,258,791 is strong in claim coverage for the enabling component (hyaluronidase) coupled with widely used nucleic acid delivery platforms.
Key strength factors
-
Single enabling element (hyaluronidase) drives both composition and method coverage.
The patent repeatedly requires hyaluronidase as the disorganizing substance, which can be a clear infringement hook if a competitor uses hyaluronidase in their delivery workflow.
-
Carrier category coverage is broad in the independent claim.
Claim 1 covers nucleic acid in an infectious viral particle or within typical non-viral cationic carriers. Claim 8 likewise covers administering hyaluronidase prior to or with those carrier systems.
-
Adenoviral vector-specific dependency increases enforceability against adenovirus programs.
Claims 3-6 and method claims 11-12 provide additional, more specific boundaries for infringement analysis against adenoviral gene therapy products that match the described vector deletions (E1 missing/absent, optional E3 and other region deletions).
-
Time-of-dosing variants reduce “timing” design-around risk.
Claims explicitly capture pre-administration, in-conjunction administration, simultaneous dosing, and sequential dosing with hyaluronidase relative to the nucleic acid carrier.
Key vulnerability factors
-
Hyaluronidase as a known drug substance may shift the real novelty focus to combination and administration method.
If competitors can frame their approach as different combinations or different delivery enhancers, they may reduce practical infringement risk unless hyaluronidase is still used as required by these claims.
-
Adenoviral deletions must match the dependent claim boundaries.
For adenovirus programs, the more specific adenoviral deletion requirements in claims 4-6 become critical. If a competing vector uses different genome architecture, region presence/absence may fall outside those dependent claim limitations.
-
“Infectious viral particle” is not equivalent to “replication-competent.”
Claim 3 requires a defective for replication adenoviral vector, but for other embodiments claim 1 and claim 8 use “infectious viral particle,” which can be litigated based on how “infectious” is satisfied by replication competence and/or particle functionality. This can become a factual/legal construction point.
When does US 6,258,791 lose exclusivity and what are the generic-entry risks?
Because US 6,258,791 is an issued patent with claims as provided, the exclusivity window is functionally tied to the US patent term and any applicable adjustments or extensions. The practical point for market entry risk is that enforcement is time-dependent and most current-market gene delivery competitors will have assessed freedom-to-operate well after issuance.
Critical limitation for current risk assessment: The claims read on gene therapy delivery approaches rather than a “small-molecule” generics scenario. “Generic entry” is not the correct framework; the operational risks are:
- whether a rival’s delivery regimen infringes composition/method/kit claims, and
- whether a rival can license or design around by avoiding hyaluronidase or changing carrier architecture and dosing sequence.
Given the absence of any timely renewal or extension data here, a current “active exclusivity” determination cannot be made from the provided record.
What do the claims require for infringement: hyaluronidase source, nucleic acid carrier, and dosing sequence?
Claim 1 and 8: what must be present?
- Hyaluronidase used as the extracellular matrix disorganizer.
- Nucleic acid present in or with a carrier:
- inside an infectious viral particle, or
- in association with cationic lipid, liposome, or cationic polymer.
Claim 2: which hyaluronidases qualify?
Claim 2 is a specificity narrowing to hyaluronate glycanohydrolases from mammalian, reptilian, hymenopteran sources; a leech salivary gland hyaluronate glycanohydrolase; or a bacterial hyaluronate lyase. Competitors using a hyaluronidase product that does not fit those categories (or that uses a differently characterized enzyme) could attempt to avoid dependent claim coverage, though independent claim 1 may still capture “hyaluronidase” more generally depending on the claim’s construction and specification support.
Claims 3-6: adenoviral vector constraints
- Recombinant adenoviral vector defective for replication (claim 3).
- Adenoviral vector comprises ITRs and an encapsidation sequence and lacks all or part of adenoviral E1 (claim 4).
- Additional optional deletions for E3 (claim 5).
- Additional optional deletions for E2, E4, L1, L2, L3, L4, L5 (claim 6).
For adenoviral infringement analysis, the key technical documentation is the vector genome map: the presence/absence of E1, and whether E3 and the specified E2/E4 and late regions are deleted or partially deleted.
Claims 8-12: timing permutations
- Prior or in conjunction (claim 8).
- Simultaneous (claim 9).
- Following hyaluronidase (claim 10).
- Adenovirus variants for the simultaneous and sequential versions (claims 11-12).
A competitor’s dosing regimen therefore needs to be tested against the timing language. Simultaneous dosing reduces the ability to argue timing design-around.
What formulations and kits are protected by US 6,258,791?
The patent protects:
- Compositions combining nucleic acid payload and hyaluronidase (claims 1-7).
- Adenovirus-based compositions meeting the described vector constraints (claims 3-6).
- Pharmaceutically acceptable excipients for administration-ready formulations (claim 7).
- Kits that include hyaluronidase plus nucleic acid in infectious viral particle form or in complexes using cationic lipid/liposome/cationic polymer (claim 13).
Practical design-around strategies would typically involve removing one of these required components from the kit, changing the enhancer away from hyaluronidase, or altering carrier class away from cationic lipid/liposome/cationic polymer while also avoiding an infectious viral particle embodiment. Whether such steps avoid infringement depends on claim construction and how broadly “hyaluronidase” and carrier categories are supported.
How does US 6,258,791 compare with other hyaluronidase-gene delivery patents?
US 6,258,791’s differentiator is that it is not limited to:
- a particular therapeutic gene, or
- a specific adenoviral subtype beyond generic recombinant defective adenoviral vectors, or
- a particular route of administration in the provided claim text.
By contrast, many other hyaluronidase patents tend to focus on improving drug dispersion, permeability, or local delivery of small molecules, or on hyaluronidase use with specific biologics. US 6,258,791 is tightly coupled to nucleic acid delivery and explicitly recites nucleic acid payload carriers.
The most relevant comparison set for business use is typically:
- patents covering hyaluronidase as a co-administered enhancer for biologics or vaccines, and
- patents covering non-viral gene delivery complexes where another extracellular matrix modulator is used instead of hyaluronidase.
Without additional patent numbers from the record, a precise citation map cannot be produced here.
What patent litigation affects US 6,258,791?
The provided input contains no litigation docket identifiers, enforcement actions, or citation chains. Without those, no accurate case-specific analysis can be generated.
What is the Orange Book status of US 6,258,791?
The Orange Book lists approved drug products with patents that protect the product. US 6,258,791 is a gene delivery technology patent, not a typical small-molecule NDA/BLA product listing. The record provided does not include any Orange Book association, FDA application number, or listed drug. A status determination cannot be made from the provided input.
What biosimilar risk exists from this patent?
Biosimilar concepts do not map cleanly to gene delivery technology patents. US 6,258,791 is not a “biosimilar” patent in the conventional sense; it is a delivery-enablement patent. The closest analogue is competitive infringement risk against next-generation viral or non-viral gene delivery regimens that include hyaluronidase.
Competitive landscape: which companies would be exposed?
Exposure would generally track any developer that:
- co-administers hyaluronidase with nucleic acid payload delivery using adenoviral vectors or cationic gene delivery systems, and
- designs products or dosing schedules that fall within the claim elements (composition, timing, vector deletions, kit inclusion).
The provided record does not identify specific companies or products. Therefore, a company-by-company exposure map cannot be produced.
Key claim-to-practice mapping table
| Claim |
Infringement anchor |
Technical elements that must match |
| 1 |
Composition scope |
Hyaluronidase + nucleic acid + carrier (infectious viral particle OR cationic lipid OR liposome OR cationic polymer) |
| 2 |
Enzyme-source narrowing |
Specific hyaluronidase classes/sources (mammalian/reptilian/hymenopteran glycanohydrolase; leech salivary; bacterial lyase) |
| 3 |
Adenovirus vector type |
Recombinant adenoviral vector defective for replication |
| 4 |
Adenovirus genome features |
ITRs + encapsidation sequence + lack all/part of E1 |
| 5 |
Optional adenovirus deletion |
Additional lack all/part of E3 |
| 6 |
Optional broader adenovirus deletions |
Lack all/part of E2/E4/L1-L5 regions |
| 7 |
Formulation readiness |
Pharmaceutically acceptable excipient |
| 8 |
Method scope |
Administer hyaluronidase prior to or in conjunction with nucleic acid carrier (viral particle OR cationic systems) |
| 9 |
Timing variant |
Simultaneous administration of hyaluronidase with viral particle/complex |
| 10 |
Timing variant |
Hyaluronidase first; viral particle/complex follows |
| 11-12 |
Adenovirus timing variants |
Adenoviral particles in simultaneous vs sequential embodiments |
| 13 |
Kit scope |
Kit with hyaluronidase + nucleic acid in carrier form described in claim 1 |
What business actions does the claim set support (licensing, FTO, or challenge)?
- Licensing leverage: The independent composition and method claims are broad on carrier classes, enabling licensing discussions that do not require a competitor to use a specific gene sequence.
- FTO design-around: Evaluate whether a competitor’s enhancer is strictly hyaluronidase versus another ECM modulator. Also evaluate dosing timing and whether adenoviral vectors meet the E1/E3/late-region deletion requirements for dependent claim coverage.
- Settlement framing: If a competitor uses hyaluronidase with adenoviral delivery, the timing and vector-deletion constraints can be used to drive targeted infringement arguments and narrowing negotiations.
Key Takeaways
- US 6,258,791 is a delivery-enabling patent: it claims compositions and methods that combine hyaluronidase with nucleic acids carried by infectious viral particles or by standard cationic/non-viral gene delivery systems.
- The adenoviral-dependent claims add enforceability against recombinant defective adenoviral vectors with specific deletion and genome-feature requirements (notably E1 absence, optional E3 and additional region deletions).
- The timing language (pre, in conjunction, simultaneous, sequential) reduces design-around opportunities based solely on dosing schedule.
- Practical risk for competitors is highest where hyaluronidase is used as the enhancer in conjunction with adenoviral and/or cationic gene delivery platforms, and where kit formulations include both components.
FAQs
1) Does US 6,258,791 cover hyaluronidase used with plasmid DNA delivered by cationic polymers?
Yes under the independent composition/method framework if the nucleic acid is carried in a complex with a cationic polymer and hyaluronidase is administered as claimed.
2) Are only adenoviral vectors covered, or do the claims also cover non-viral delivery systems?
Both. Adenovirus is explicitly covered via dependent claims, while claim 1 and claim 8 also cover cationic lipid/liposome/cationic polymer delivery systems.
3) Can a competitor avoid infringement by changing adenovirus serotype or promoter?
Changing promoter or serotype alone does not avoid claim coverage if the vector still meets the dependent claim structural limitations (ITRs, encapsidation sequence, and region deletions for E1 and optionally E3 and E2/E4/L1-L5).
4) Does simultaneous dosing matter for infringement?
Yes. Claims 9 and 11 explicitly cover simultaneous administration of hyaluronidase with the nucleic acid carrier, including adenoviral particles.
5) Is a “kit” required for infringement?
No. The kit is claim 13. Independent composition and method claims can be infringed without providing a kit, depending on how products are administered.
References (APA)
- United States Patent 6,258,791. (n.d.). Claims text as provided in prompt.
